The company reported second-quarter sales of $100.4 million, versus $98.6 million a year earlier. Excluding $9.9 million of net sales related to the sale of its synthetic DNA business unit in the second quarter of 2004, consolidated net sales increased 13 percent from $88.7 million in 2004.
R&D costs for the period increased to $9.4 million from $9.3 million year over year.
Qiagen's net income for the quarter climbed 57 percent to $13.8 million, or $.09 per share, compared with $8.8 million, or $.06 per share, in the year-ago quarter.
Qiagen said it had around $157 million cash and equivalents, and $51.8 million in marketable securities as of June 30.